Tema Etfs LLC Has $3.62 Million Stock Holdings in Amgen Inc. $AMGN

Tema Etfs LLC increased its holdings in Amgen Inc. by 33.3% in Q2, owning 12,977 shares worth $3.62 million. Analysts have mixed ratings on Amgen, with a consensus target price of $335.65. Amgen reported strong quarterly earnings, beating estimates with $5.64 EPS and $9.56 billion revenue. The company announced a quarterly dividend of $2.38 per share, yielding 2.8%. Amgen's stock performance shows a one-year high of $346.38.

Tema Etfs LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 33.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,977 shares of the medical research company's stock after purchasing an additional 3,243 shares during the quarter. Tema Etfs LLC's holdings in Amgen were worth $3,623,000 as of its most recent SEC filing.

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

Several other institutional investors and hedge funds have also modified their holdings of AMGN. Wealth Preservation Advisors LLC acquired a new stake in shares of Amgen in the first quarter worth about $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen during the 2nd quarter valued at about $27,000. CBIZ Investment Advisory Services LLC raised its stake in shares of Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock valued at $29,000 after acquiring an additional 85 shares in the last quarter. Evelyn Partners Investment Management LLP bought a new position in shares of Amgen in the 2nd quarter valued at approximately $32,000. Finally, Activest Wealth Management lifted its holdings in Amgen by 3,433.3% in the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company's stock worth $33,000 after purchasing an additional 103 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of several analyst reports. Wells Fargo & Company set a $400.00 price target on Amgen in a report on Tuesday, November 25th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Amgen from $280.00 to $285.00 and gave the company a "hold" rating in a research note on Tuesday, November 11th. Truist Financial initiated coverage on shares of Amgen in a report on Monday, November 24th. They issued a "hold" rating and a $318.00 target price on the stock. Scotiabank assumed coverage on shares of Amgen in a report on Thursday, November 13th. They set a "sector outperform" rating and a $385.00 price target for the company. Finally, Bank of America raised their price target on Amgen from $261.00 to $272.00 and gave the company an "underperform" rating in a research report on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Amgen has an average rating of "Moderate Buy" and a consensus target price of $335.65.

Amgen Stock: New All-Time Highs Ahead After Earnings Beat

Check Out Our Latest Analysis on Amgen

Amgen Price Performance

NASDAQ:AMGN opened at $340.16 on Friday. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. Amgen Inc. has a one year low of $253.30 and a one year high of $346.38. The company has a fifty day moving average price of $312.27 and a 200 day moving average price of $296.72. The stock has a market cap of $183.17 billion, a P/E ratio of 26.29, a PEG ratio of 3.12 and a beta of 0.45.

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same period last year, the business posted $5.58 EPS. The business's quarterly revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, November 21st. This represents a $9.52 annualized dividend and a yield of 2.8%. Amgen's dividend payout ratio is 73.57%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the business's stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 890 shares of the company's stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares of the company's stock, valued at $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 in the last quarter. Corporate insiders own 0.76% of the company's stock.

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Should You Invest $1,000 in Amgen Right Now?

Before you consider Amgen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.

While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here